This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (34) Citing Articles via Google Scholar Google Scholar Articles by Ziegenhagen, M.W. Articles by Müller-Quernheim, J. Search for Related Content PubMed PubMed Citation Articles by Ziegenhagen, M.W. Articles by Müller-Quernheim, J.

Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis

¹ Dept of Pneumology, University Hospital Freiburg, Freiburg, and ² Medical Hospital, Research Centre Borstel, Borstel, Germany

CORRESPONDENCE: M.W. Ziegenhagen, Dept of Pneumology, University Hospital Freiburg, Kilianstr. 5, 79106, Freiburg, Germany. Fax: 49 7612707437. E-mail: ziegenhagen@med1.ukl.uni-freiburg.de

Keywords: bronchoalveolar lavage, disease severity, eosinophils, neutrophils, sarcoidosis

Received: July 17, 2001
Accepted November 4, 2002

This study was supported, in part, by a grant from the German Research Council, Bonn, Germany (No. MU 692-3/3).

The aim of the present study was to determine which bronchoalveolar lavage fluid (BALF) and serological parameters reflect the severity of newly diagnosed pulmonary sarcoidosis.

Seventy-four previously untreated sarcoid patients were categorised into three groups: 10 patients with Löfgren's syndrome, 51 patients with stable disease and 13 patients with progressing disease requiring systemic steroid treatment.

Total BALF cell count, percentage of alveolar lymphocytes and lymphocyte CD4/CD8 ratio were not associated with severity of disease. Interestingly, a significant increase in percentages of BALF neutrophils (5.2±1.1%) and eosinophils (1.7±0.6%) was observed in sarcoid patients with progressing disease. Elevated percentages of these two cell types were the only BALF parameters associated with a more frequent necessity for systemic steroid therapy. This association between an elevated percentage of BALF neutrophils and the necessity for steroid treatment was observed in advanced as well as early sarcoidosis (radiological types I and II). Serum levels of soluble interleukin-2 receptor and neopterin were significantly elevated in progressing disease compared to stable disease or Löfgren's syndrome.

The present results demonstrate that increased percentages of neutrophils (>3.0%) and eosinophils (>1%) in bronchoalveolar lavage fluid from newly diagnosed pulmonary sarcoidosis is associated with a significantly higher risk of necessity for steroid therapy and may be helpful markers of progressive disease. Furthermore, of the serological parameters investigated, only serum levels of soluble interleukin-2 receptor and neopterin were associated with disease severity.

This article has been cited by other articles:

				J. P. Lynch III Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia/Fibrosis, and Sarcoidosis ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 635 - 686. [Full Text] [PDF]

				A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui Interstitial lung disease guideline Thorax, September 1, 2008; 63(Suppl_5): v1 - v58. [Full Text] [PDF]

				N. Milman and A. L. Hoffmann Childhood sarcoidosis: long-term follow-up Eur. Respir. J., March 1, 2008; 31(3): 592 - 598. [Abstract] [Full Text] [PDF]

				A. Prasse, C. Katic, M. Germann, A. Buchwald, G. Zissel, and J. Muller-Quernheim Phenotyping Sarcoidosis from a Pulmonary Perspective Am. J. Respir. Crit. Care Med., February 1, 2008; 177(3): 330 - 336. [Abstract] [Full Text] [PDF]

				W. J. Piotrowski, A. Antczak, J. Marczak, A. Nawrocka, Z. Kurmanowska, and P. Gorski Eicosanoids in Exhaled Breath Condensate and BAL Fluid of Patients With Sarcoidosis Chest, August 1, 2007; 132(2): 589 - 596. [Abstract] [Full Text] [PDF]

				H. Biller, G. Zissel, B. Ruprecht, M. Nauck, A. Busse Grawitz, and J. Muller-Quernheim Genotype-corrected reference values for serum angiotensin-converting enzyme Eur. Respir. J., December 1, 2006; 28(6): 1085 - 1091. [Abstract] [Full Text] [PDF]

				H.-J. Kabitz, F. Lang, S. Walterspacher, S. Sorichter, J. Muller-Quernheim, and W. Windisch Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest, November 1, 2006; 130(5): 1496 - 1502. [Abstract] [Full Text] [PDF]

				K. M. Antoniou, A. Tzouvelekis, M. G. Alexandrakis, K. Sfiridaki, I. Tsiligianni, G. Rachiotis, N. Tzanakis, D. Bouros, J. Milic-Emili, and N. M. Siafakas Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest, October 1, 2006; 130(4): 982 - 988. [Abstract] [Full Text] [PDF]

				T F Logan and E S Bensadoun Increased disease activity in a patient with sarcoidosis after high dose interleukin 2 treatment for metastatic renal cancer Thorax, July 1, 2005; 60(7): 610 - 611. [Abstract] [Full Text] [PDF]

				S. Rothkrantz-Kos, M. P. van Dieijen-Visser, P. G.H. Mulder, and M. Drent Potential Usefulness of Inflammatory Markers to Monitor Respiratory Functional Impairment in Sarcoidosis Clin. Chem., September 1, 2003; 49(9): 1510 - 1517. [Abstract] [Full Text] [PDF]